Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Commissioner Califf Expects To Leave Post Following 2024 Elections

Jul 14 2022

• By Derrick Gingery

Robert Califf at Alliance for a Stronger FDA — • Source: Screenshot

Related Content

Q&A: FDA Chief Califf Talks Clinical Trial Diversity, Using AI/ML For Inspections, User Fees, And More

Jul 13 2022

Robert Califf Likely To Find Many Familiar Problems Upon His Return To US FDA

Nov 12 2021

Califf On Getting Someone Younger Than 70 To Take FDA Commissioner Job

May 03 2022

Dr. Califf Returns To US FDA: What To Do First?

Feb 15 2022

Califf: More Expedited Approvals Mean US Clearance Only The Beginning Of Learning About Medical Products

Jun 21 2022

US FDA/Industry Thinking PDUFA VIII Could Be A Hybrid Negotiation

Jun 22 2022

Califf Says Opioid Labeling Changes, Withdrawals Still Possible

Apr 13 2022

Sen. Burr Worries Rising User Fees Helping US FDA Evade Congressional Oversight

Apr 06 2022

US FDA’s Califf Expects Advisory Committee Reform Talk ‘About A Year From Now’

Apr 29 2022

Potential For Califf’s Second US FDA Commissioner Term Surprises, Excites Stakeholders

Oct 15 2021

Additional Topics

International United States US States FDA Leadership Politics Commercial Compliance Consumer Cosmetics Elections Guidance Documents Manufacturing OTC Drugs Policy Regulation Dietary Supplements User Fees

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window